Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Retained Earnings (2020 - 2022)

Atea Pharmaceuticals has reported Retained Earnings over the past 3 years, most recently at -$25.4 million for Q3 2022.

  • Quarterly results put Retained Earnings at -$25.4 million for Q3 2022, up 58.35% from a year ago — trailing twelve months through Sep 2022 was -$25.4 million (up 58.35% YoY), and the annual figure for FY2021 was $56.0 million, up 185.99%.
  • Retained Earnings for Q3 2022 was -$25.4 million at Atea Pharmaceuticals, down from -$17.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for AVIR hit a ceiling of $56.0 million in Q4 2021 and a floor of -$85.8 million in Q3 2020.
  • Median Retained Earnings over the past 3 years was -$32.9 million (2021), compared with a mean of -$28.0 million.
  • Peak annual rise in Retained Earnings hit 185.99% in 2021, while the deepest fall reached 28.8% in 2021.
  • Atea Pharmaceuticals' Retained Earnings stood at -$65.2 million in 2020, then surged by 185.99% to $56.0 million in 2021, then crashed by 145.42% to -$25.4 million in 2022.
  • The last three reported values for Retained Earnings were -$25.4 million (Q3 2022), -$17.4 million (Q2 2022), and $14.0 million (Q1 2022) per Business Quant data.